Alcon strategy in focus, ophthalmic stock attracts long-term investors

Alcon Inc, the eye-care specialist listed on the SIX Swiss Exchange, continues to draw attention from long-term investors with its surgical and vision-care focus, global scale and integration of recent acquisitions in premium intraocular lenses and dry-eye treatments.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:35.

Alcon Inc (CH0432492467) positions itself as a pure-play global eye-care leader with a focus on surgical equipment and vision-care products. The company is listed on the SIX Swiss Exchange in Zurich and reports in US dollars after its spin-off from Novartis in 2019.

How Alcon earns its revenue

Alcon divides its business into two main segments: Surgical and Vision Care, which together generated more than 9 billion US dollars in annual net sales in 2024 according to company disclosures. The Surgical unit covers cataract, refractive and vitreoretinal procedures, while Vision Care focuses on contact lenses and ocular-health products.

In the Surgical segment, Alcon sells phacoemulsification systems, femtosecond lasers, intraocular lenses and related consumables that are used in cataract operations worldwide. The company highlights the growing demand for premium and toric intraocular lenses as a structural driver, supported by aging populations and rising access to eye care in emerging markets.

Global footprint and competitive landscape

Alcon generates a significant part of its revenue in the United States, Europe and Japan, but also reports increasing contributions from fast-growing markets in Asia and Latin America. Competitors in various segments include Johnson & Johnson Vision, Bausch + Lomb and HOYA, which also provide surgical equipment and contact lenses to ophthalmologists and optical retailers.

The eye-care market is supported by long-term demographic trends, including higher life expectancy and increased screen time that can contribute to myopia and dry-eye symptoms. These factors support demand for cataract surgery, refractive procedures and contact lenses, areas in which Alcon is active with branded solutions for consumers and physicians.

What the company sells to surgeons

One key representative product line in Alcon's portfolio is the AcrySof family of intraocular lenses, which is widely used in cataract surgery and includes monofocal, toric and multifocal designs. The company also markets phacoemulsification systems such as Centurion that enable efficient removal of cataracts during surgery.

Where the stock trades today

Alcon stock trades on the SIX Swiss Exchange in Zurich under the ticker ALC, quoted in Swiss francs. The listing reflects the company's Swiss domicile following its separation from Novartis, while reporting and guidance are provided in US dollars for global investors.

Alcon at a glance

• Company: Alcon Inc
• ISIN: CH0432492467
• WKN: A2PHVF
• Ticker: ALC
• Trading venue: SIX Swiss Exchange (Zurich)
• Price (as of 2026-06-27, 11:30): 79.50 CHF
• Market cap: 39.0 billion CHF (as of 2026-06-27)
• Sector / industry: Health Care / Medical Equipment
• Index membership: SMI Mid (SMIM)
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.